RespireRx Pharmaceuticals Inc
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, … Read more
RespireRx Pharmaceuticals Inc (RSPI) - Total Liabilities
Latest total liabilities as of September 2023: $12.41 Million USD
Based on the latest financial reports, RespireRx Pharmaceuticals Inc (RSPI) has total liabilities worth $12.41 Million USD as of September 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
RespireRx Pharmaceuticals Inc - Total Liabilities Trend (1988–2022)
This chart illustrates how RespireRx Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
RespireRx Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of RespireRx Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UNITED PARCEL SVC-B - Dusseldorf Stock Exchang
DU:UPAB
|
Germany | €51.38 Billion |
|
E2Gold Inc
OTCQB:ETUGF
|
USA | $1.30 Million |
|
Identillect Technologies Corp
V:ID
|
Canada | CA$1.75 Million |
|
MTI Investment SE
ST:MTI
|
Sweden | Skr24.45 Million |
|
Osmosun SA
PA:ALWTR
|
France | €2.84 Million |
|
AMEDISYS
BE:ADY
|
Germany | €938.67 Million |
|
CCSC Technology International Holdings Limited Ordinary Shares
NASDAQ:CCTG
|
USA | $675.92K |
|
Tombill Mines Limited
PINK:TBLLF
|
USA | $136.23K |
Liability Composition Analysis (1988–2022)
This chart breaks down RespireRx Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 114.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how RespireRx Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for RespireRx Pharmaceuticals Inc (1988–2022)
The table below shows the annual total liabilities of RespireRx Pharmaceuticals Inc from 1988 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $11.90 Million | +16.51% |
| 2021-12-31 | $10.22 Million | +25.38% |
| 2020-12-31 | $8.15 Million | +8.79% |
| 2019-12-31 | $7.49 Million | +27.87% |
| 2018-12-31 | $5.86 Million | +28.73% |
| 2017-12-31 | $4.55 Million | -20.55% |
| 2016-12-31 | $5.73 Million | +90.40% |
| 2015-12-31 | $3.01 Million | +15.66% |
| 2014-12-31 | $2.60 Million | -38.66% |
| 2013-12-31 | $4.24 Million | +32.87% |
| 2012-12-31 | $3.19 Million | +178.75% |
| 2011-12-31 | $1.14 Million | -1.65% |
| 2010-12-31 | $1.16 Million | -47.89% |
| 2009-12-31 | $2.23 Million | +27.23% |
| 2008-12-31 | $1.76 Million | +0.22% |
| 2007-12-31 | $1.75 Million | -17.15% |
| 2006-12-31 | $2.11 Million | -25.98% |
| 2005-12-31 | $2.86 Million | -54.41% |
| 2004-12-31 | $6.27 Million | +74.08% |
| 2003-12-31 | $3.60 Million | +0.75% |
| 2002-12-31 | $3.57 Million | -34.09% |
| 2001-12-31 | $5.42 Million | 0.00% |
| 2000-12-31 | $5.42 Million | +377.67% |
| 1999-12-31 | $1.13 Million | -33.73% |
| 1998-12-31 | $1.71 Million | -56.16% |
| 1997-12-31 | $3.91 Million | +126.00% |
| 1996-12-31 | $1.73 Million | +8.02% |
| 1995-12-31 | $1.60 Million | 0.00% |
| 1994-12-31 | $1.60 Million | +128.57% |
| 1993-12-31 | $700.00K | +89.19% |
| 1992-12-31 | $370.00K | -55.42% |
| 1991-12-31 | $830.00K | +167.74% |
| 1990-12-31 | $310.00K | +34.78% |
| 1989-12-31 | $230.00K | +76.92% |
| 1988-12-31 | $130.00K | -- |